Evaluating Autologous Stromal Vascular Fraction in Subjects with Vocal Fold Scar

A Pilot Study Evaluating the Safety and Feasibility of Autologous Stromal Vascular Fraction in Subjects with Vocal Fold Scar

The purpose of this research study is to assess if autologous Stromal Vascular Fraction (SVF) taken from the stomach or hips can help heal vocal fold scars.

Study Overview

• Status: Terminated
• Conditions: Vocal Fold Scars
• Intervention / Treatment: Biological: Autologous adipose derived SVF

• Study Type: Interventional
• Enrollment (Actual): 2
• Phase: Phase 1

Contacts and Locations

Study Locations

• United States
  • Florida
    • Jacksonville, Florida, United States, 32224
      • Mayo Clinic Florida

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years to 65 years (Adult, Older Adult)
• Accepts Healthy Volunteers: No

Description

Inclusion Criteria:

• Signed informed consent
• Subject's age between 18 and < 80-years-old
• Voice handicap index greater than 10/40
• Scarred vocal folds or congenital sulcus or after vocal fold surgery (Scarring will be scored during examination and identification of scarred vocal folds and hoarseness. This criterion includes the lack of or decreased mucosal wave of the vocal fold during videostroboscopy exam. Scoring of scar based on laryngoscopic exam: Type I: atrophy of lamina propria with/without affected epithelium. Type II: the epithelium, lamina propria, and muscle are affected. Type III: scar located on the anterior commissure. Type IV: this category includes extended scar formation in both anteroposterior and rostro-caudal axis, with significant loss of vocal fold mass)
• Unilateral or Bilateral vocal fold scarring
• At least 1-year delay after initial surgery
• Negative pregnancy test and contraception for woman of childbearing age. Women of childbearing age must use contraception at least 4 months pre and post SVF administration.

Exclusion Criteria:

• Refusal of speech therapy
• History of malignant lesion or severe dysplasia of the scarred vocal fold
• Contraindication to anesthesia, anticoagulant treatment, coagulation disorders, active infectious disease
• Refusal or inability to comply with study procedures
• Pregnant and lactating woman

• Major chronic medical condition that could affect treatment or quality of SVF product. These include:

  • Current treatment or within 6 months of last treatment for cancer.
  • Blindness
  • Known history of Dementia,
  • Known history of Kidney Disease
  • Known history of Cerebral Vascular Accident or Stroke
• Known history of Diabetes
• Abnormal screening lab. If the laboratory reports a single, non-clinically relevant, non-life-threatening result for any of these studies and is the only excluding factor it may be repeated 1 week later if the subject wishes. Normalization of that laboratory study will then be considered non-exclusionary.
• Post-Radiation scarring of vocal folds.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: N/A
• Interventional Model: Single Group Assignment
• Masking: None (Open Label)

Number of Arms

1

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: SVF for treating scarred vocal folds; Subject identified with scarred vocal folds will have autologous adipose derived SVF harvested and applied to scarred vocal folds.	Biological: Autologous adipose derived SVF; A single dose of autologous adipose derived SVF isolated from adipose tissue will be administered to scarred vocal folds.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Adverse events post SVF administration	Number of adverse events related to SVF via endoscopy into vocal folds defined as inflammation or swelling indicated by red or swollen vocal folds or evidence of a hemorrhage indicated by a bleed at or near the site of delivery. This will be evaluated during stroboscope exam.	24 months

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Voice handicap Index	Change in the self-reported voice handicap index to describe voices and effects of voices on subject lives, measure using a total score range from 0-120; 0-30=mild, 31-60=moderate, 60-120=severe	Baseline, Week 1, and Months 1, 3, 6, 9, 12, and 24

Collaborators and Investigators

• Sponsor: Shane A. Shapiro
• Investigators: Principal Investigator: Amy Rutt, DO, Mayo Clinic

Publications and helpful links

Helpful Links

• Mayo Clinic Clinical Trials

Study record dates

Study Major Dates

• Study Start (Actual): August 1, 2021
• Primary Completion (Actual): December 5, 2024
• Study Completion (Actual): December 5, 2024

Study Registration Dates

• First Submitted: April 26, 2022
• First Submitted That Met QC Criteria: April 26, 2022
• First Posted (Actual): April 29, 2022

Study Record Updates

• Last Update Posted (Actual): March 25, 2025
• Last Update Submitted That Met QC Criteria: December 16, 2024
• Last Verified: June 1, 2024

More Information

Terms related to this study

• Other Study ID Numbers: 19-006564

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: Yes
• Studies a U.S. FDA-regulated device product: No
• product manufactured in and exported from the U.S.: No